These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11890474)

  • 21. Strategies for bringing drug delivery tools into discovery.
    Kwong E; Higgins J; Templeton AC
    Int J Pharm; 2011 Jun; 412(1-2):1-7. PubMed ID: 21421040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxicologic pathology in the new millennium.
    Ettlin RA; Leininger JR
    Toxicol Pathol; 2002; 30(1):160-3. PubMed ID: 11890471
    [No Abstract]   [Full Text] [Related]  

  • 24. Genomics and systems biology--how relevant are the developments to veterinary pharmacology, toxicology and therapeutics?
    Witkamp RF
    J Vet Pharmacol Ther; 2005 Jun; 28(3):235-45. PubMed ID: 15953196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Key challenges for toxicologists in the 21st century.
    Smith LL
    Trends Pharmacol Sci; 2001 Jun; 22(6):281-5. PubMed ID: 11395155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stem cell models for drug discovery and toxicology studies.
    Liu W; Deng Y; Liu Y; Gong W; Deng W
    J Biochem Mol Toxicol; 2013 Jan; 27(1):17-27. PubMed ID: 23293059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future of toxicology--low-dose toxicology and risk--benefit analysis.
    Rietjens IM; Alink GM
    Chem Res Toxicol; 2006 Aug; 19(8):977-81. PubMed ID: 16918235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive in silico off-target profiling in drug discovery.
    Schmidt F; Matter H; Hessler G; Czich A
    Future Med Chem; 2014 Mar; 6(3):295-317. PubMed ID: 24575966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iconix Biosciences, Inc.
    Fielden MR; Halbert DN
    Pharmacogenomics; 2007 Apr; 8(4):401-5. PubMed ID: 17391077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testing paradigm for prediction of development-limiting barriers and human drug toxicity.
    Sasseville VG; Lane JH; Kadambi VJ; Bouchard P; Lee FW; Balani SK; Miwa GT; Smith PF; Alden CL
    Chem Biol Interact; 2004 Nov; 150(1):9-25. PubMed ID: 15522258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic profiling as a tool for understanding mechanisms of toxicity.
    Clarke CJ; Haselden JN
    Toxicol Pathol; 2008 Jan; 36(1):140-7. PubMed ID: 18337232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathology in drug discovery and development.
    Jubb AM; Koeppen H; Reis-Filho JS
    J Pathol; 2014 Jan; 232(2):99-102. PubMed ID: 24122335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response letter from Clinical Pathology Interest Group of the Society of Toxicologic Pathology (STP) for manuscript entitled International recommendations for training future toxicologic pathologists participating in regulatory-type, nonclinical toxicity studies by Bolon et al.
    Tripathi NK; Schultze AE; Pearson RC; Everds NE; Elliott GS; Ramaiah L; Wells MY; Latimer KS; Walter GL; Katavolos P; Collins ND; Tarrant J; Walker DB; Topper MJ; Jordan HL; O'Rourke LG; Guilpin VB; Brockus CW; Wilcox AL; Clemo FA; Smith GS; Reagan WJ; McCartney JE
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):39. PubMed ID: 21676604
    [No Abstract]   [Full Text] [Related]  

  • 36. A brief review of modern toxicologic pathology in regulatory and explanatory toxicity studies of chemicals.
    Ettlin RA; Oberholzer M; Perentes E; Ryffel B; Kolopp M; Qureshi SR
    Arch Toxicol; 1991; 65(6):445-53. PubMed ID: 1929864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Computational toxicology as implemented by the U.S. EPA: providing high throughput decision support tools for screening and assessing chemical exposure, hazard and risk.
    Kavlock R; Dix D
    J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):197-217. PubMed ID: 20574897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how.
    Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
    Drug Discov Today; 2014 Aug; 19(8):1131-6. PubMed ID: 24368175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive toxicology in drug discovery--second international conference. New technologies for predicting toxic responses at an early stage. 10-11 November 1999, New Orleans, LA, USA.
    Tugwood J
    IDrugs; 2000 Feb; 3(2):179-81. PubMed ID: 16107935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.